Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas
Authors:
- 1 February 2010
- journal article
- Published by Elsevier in Laboratory Investigation
- Vol. 23 (2) , 159-168
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical OncologyJournal of Clinical Oncology, 2009
- Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco ControlJNCI: Journal of the National Cancer Institute, 2008
- Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid StructuresJournal of Clinical Oncology, 2008
- Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung CancerClinical Cancer Research, 2008
- Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patientsLung Cancer, 2008
- Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar FeaturesThe Journal of Molecular Diagnostics, 2007
- Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinomaBritish Journal of Cancer, 2006
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004